Law Extract Following the enactment of the Agreement on Trade Related Aspects of Intellectual Property TRIPSthe evidence presented from the experiences of local pharmaceutical industries in developing countries hereinafter referred as local pharmaceutical industry strongly suggests that there has been a dramatic change in the business climate.
Under the agreement, Teva will be the exclusive marketer and distributor in Israel of an inhaler developed by Syqe Medical for the delivery of medical cannabis.
The accord marks the first time that a major global pharma company has agreed to market a medical cannabis product, according to Syqe. This makes it the first hospital in the world to prescribe cannabis as a standard medical treatment. Medical cannabis is the first plant to be used in the inhaler.
Until now, the quantities of active ingredients inhaled from cannabis have generally been unknown. In the absence of precise dosing, cannabis could not be prescribed as a standard medical treatment, causing difficulties for patients and the physicians who treat them.
Syqe Medical Chairman Dr. Eytan Hyam Courtesy Syqe Medical says its inhaler will allow cannabis to be regarded as a standard medical treatment, with precise control over dosage, tailored to patients, and their pain.
Another advantage of the inhaler is that it is a convenient and accessible option for patients who are reluctant to smoke cannabis. Syqe Medical chairman Dr. Teva Israel CEO Avinoam Sapir Courtesy According to data provided by the companies, for there are about 26, patients licensed to use medical cannabis in Israel, some 90 percent of whom smoke it.
The number of licenses is expected to double by The ability to do so forms the basis for administering proper treatment and conducting significant scientific research.
The development of this inhaler fulfills our greatest hopes, to be able to administer accurate and reliable doses of cannabis. It constitutes a breakthrough in cannabis treatment and the medical use of cannabis in Israel and around the world. They will be marketed and distributed by Teva Israel to relevant parties, including doctors, nurses, hospitals, pain clinics, oncology clinics and pharmacies.
The Syqe inhaler is intended for patients suffering a variety of illnesses, based on indications approved by the Health Ministry.
Teva Israel and Syqe Medical are also setting up a support and training system for patients and medical professionals, consisting of a team of nurses to be established especially for this purpose.Teva Pharmaceutical is successfully converting patients to a new long Teva Pharmaceutical's Strategy Proves to be Brilliant and Teva's "switching" strategy has shored-up billions of.
Global Human Resources Executive with over 20 years of leadership experience in Pharmaceutical and Healthcare industries across multiple cultures and geographies. Results-oriented leader demonstrated success in driving talent strategies that enable business timberdesignmag.com: VP, HR Business Partner, Global .
Teva Pharmaceutical Industries Ltd. ADR stock price, stock quotes and financial overviews from MarketWatch.
Pharmaceutical Pricing Strategy Global Pricing Strategies November 17th, - For your pharmaceutical pricing strategy Alliance Life Science s Pricentric tool helps develop a pricing plan and maintain Different Pricing Strategies of Teva Pharmaceuticals November 14th, - Different Pricing Strategies of Teva Pricing.
Teva Pharmaceuticals Embarks on Strategic Corporate Identity Program to Build a Global Brand. JERUSALEM--(BUSINESS WIRE)--Feb. 24, Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it is embarking on a strategic enterprise-wide corporate identity program to build a global brand.
This is the manifestation of the journey Teva . Business-Level Strategy Teva Pharmaceutical Industries, Ltd MGMT , Fall, Instructors: Professor Bilgili & Professor Reddy Global Have these changes been in Teva's favor?
YES! Corporate-level Strategy Teva focus on the pharmaceutical filed Teva's Future The Generic pharmaceuticals Teva's Future.